Identification

Name
Aripiprazole
Accession Number
DB01238  (APRD00638)
Type
Small Molecule
Groups
Approved, Investigational
Description

Aripiprazole is an atypical antipsychotic medication used for the treatment of schizophrenia. It has also recently received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder. Aripiprazole appears to mediate its antipsychotic effects primarily by partial agonism at the D2 receptor. In addition to partial agonist activity at the D2 receptor, aripiprazole is also a partial agonist at the 5-HT1A receptor, and like the other atypical antipsychotics, aripiprazole displays an antagonist profile at the 5-HT2A receptor. Aripiprazole has moderate affinity for histamine and alpha adrenergic receptors, and no appreciable affinity for cholinergic muscarinic receptors.

Structure
Thumb
Synonyms
  • Abilitat
  • Aripiprazol
  • Aripiprazole
  • Aripiprazolum
  • OPC 31
External IDs
OPC-14597 / OPC-31
Product Ingredients
IngredientUNIICASInChI Key
Aripiprazole lauroxilB786J7A3431259305-29-7DDINXHAORAAYAD-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AbilifyTablet10 mg/1OralCardinal Health2002-11-15Not applicableUs
AbilifyTablet15 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2010-06-03Not applicableUs
AbilifyTablet30 mg/1OralOtsuka Pharmaceutical Co., Ltd.2002-11-15Not applicableUs59148 0011 13 nlmimage10 a31551ca
AbilifyTablet10 mg/1Oralbryant ranch prepack2002-11-15Not applicableUs
AbilifyTablet5 mg/1OralStat Rx USA2002-11-15Not applicableUs
AbilifyTablet2.0 mgOralBristol Myers Squibb2009-09-30Not applicableCanada
AbilifyTablet5 mg/1OralRemedy Repack2013-05-102016-03-31Us
AbilifyTablet30.0 mgOralBristol Myers Squibb2009-09-30Not applicableCanada
AbilifyTablet30 mg/1OralAphena Pharma Solutions Tennessee, Inc.2002-11-15Not applicableUs
AbilifyTablet10 mg/1OralOtsuka Pharmaceutical Co., Ltd.2002-11-15Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AbilifyTablet15 mg/1OralRemedy Repack2010-12-142015-12-29Us
AripiprazoleTablet30 mg/1OralAjanta Pharma Limited2016-08-27Not applicableUs
AripiprazoleTablet10 mg/1OralAurobindo Pharma2015-10-08Not applicableUs
AripiprazoleTablet30 mg/1OralAv Pak2016-04-28Not applicableUs31722 0830 30 nlmimage10 b54ddabe
AripiprazoleTablet2 mg/1OralTrigen Laboratories, Inc.2015-04-28Not applicableUs
AripiprazoleTablet5 mg/1OralAlembic Pharmaceuticals Limited2015-04-28Not applicableUs
AripiprazoleTablet5 mg/1OralAmneal Pharmaceuticals2016-06-20Not applicableUs
AripiprazoleTablet2 mg/1OralAjanta Pharma Limited2016-08-27Not applicableUs
AripiprazoleTablet15 mg/1OralExelan Pharmaceuticals, Inc.2015-04-28Not applicableUs
AripiprazoleTablet30 mg/1OralAccord Healthcare Limited2017-01-30Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AripiprazoleTablet5 mg/1OralAphena Pharma Solutions Tennessee, Inc.2015-07-28Not applicableUs
International/Other Brands
Abilify / Abilitat
Categories
UNII
82VFR53I78
CAS number
129722-12-9
Weight
Average: 448.385
Monoisotopic: 447.148032537
Chemical Formula
C23H27Cl2N3O2
InChI Key
CEUORZQYGODEFX-UHFFFAOYSA-N
InChI
InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)
IUPAC Name
7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one
SMILES
ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl

Pharmacology

Indication

For the treatment of schizophrenia and related psychotic disorders.

Structured Indications
Pharmacodynamics

Aripiprazole is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Aripiprazole is a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), 1 and 2 adrenergic, and H1 histaminergic receptors. Aripiprazole acts as an antagonist at other receptors, but with lower potency. Antagonism at receptors other than dopamine and 5HT2 with similar receptor affinities may explain some of the other therapeutic and side effects of Aripiprazole. Aripiprazole's antagonism of histamine H1 receptors may explain the somnolence observed with this drug. Aripiprazole's antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug.

Mechanism of action

Aripiprazole's antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia.

TargetActionsOrganism
A5-hydroxytryptamine receptor 2A
antagonist
Human
AD(2) dopamine receptor
antagonist
partial agonist
Human
U5-hydroxytryptamine receptor 1A
antagonist
partial agonist
Human
U5-hydroxytryptamine receptor 1B
antagonist
Human
U5-hydroxytryptamine receptor 1D
antagonist
Human
U5-hydroxytryptamine receptor 1E
antagonist
Human
U5-hydroxytryptamine receptor 2C
antagonist
Human
U5-hydroxytryptamine receptor 3A
antagonist
Human
U5-hydroxytryptamine receptor 6
antagonist
Human
U5-hydroxytryptamine receptor 7
antagonist
Human
UD(1A) dopamine receptor
antagonist
partial agonist
Human
UD(1B) dopamine receptor
antagonist
partial agonist
Human
UD(3) dopamine receptor
antagonist
partial agonist
Human
UD(4) dopamine receptor
antagonist
partial agonist
Human
NHistamine H1 receptor
antagonist
Human
NAlpha-1A adrenergic receptor
antagonist
Human
NAlpha-1B adrenergic receptor
antagonist
Human
NAlpha-2A adrenergic receptor
antagonist
Human
NAlpha-2B adrenergic receptor
antagonist
Human
NAlpha-2C adrenergic receptor
antagonist
other/unknown
Human
NMuscarinic acetylcholine receptor M1
antagonist
Human
NMuscarinic acetylcholine receptor M2
antagonist
Human
NMuscarinic acetylcholine receptor M3
antagonist
Human
NMuscarinic acetylcholine receptor M4
antagonist
Human
NMuscarinic acetylcholine receptor M5
antagonist
Human
Absorption
Not Available
Volume of distribution
  • 4.9 L/kg
Protein binding

>99%

Metabolism

Hepatic.

Route of elimination

Less than 1% of unchanged aripiprazole was excreted in the urine and approximately 18% of the oral dose was recovered unchanged in the feces.

Half life

75-146 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2D6CYP2D6*3Not AvailableC alleleEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*4Not AvailableC alleleEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*6Not Available1707delTEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower dose requirement.Details

Interactions

Drug Interactions
DrugInteractionDrug group
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Aripiprazole.Investigational
2,5-Dimethoxy-4-ethylamphetamineAripiprazole may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineAripiprazole may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineAripiprazole may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Aripiprazole can be increased when it is combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Aripiprazole.Approved, Investigational
AcebutololAripiprazole may increase the hypotensive activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Aripiprazole can be decreased when it is combined with Acetaminophen.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Aripiprazole.Investigational, Withdrawn
AdipiplonThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Agomelatine.Approved, Investigational
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Aripiprazole.Experimental, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Alaproclate.Experimental
AlclometasoneThe serum concentration of Aripiprazole can be decreased when it is combined with Alclometasone.Approved
AldesleukinAripiprazole may increase the hypotensive activities of Aldesleukin.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Aripiprazole.Approved, Illicit
AlimemazineThe serum concentration of Aripiprazole can be decreased when it is combined with Alimemazine.Approved, Vet Approved
AliskirenAripiprazole may increase the hypotensive activities of Aliskiren.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Aripiprazole.Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Aripiprazole.Approved, Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Aripiprazole.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Aripiprazole.Approved, Illicit, Investigational
AmantadineThe therapeutic efficacy of Amantadine can be decreased when used in combination with Aripiprazole.Approved
AmifostineAripiprazole may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideAripiprazole may increase the hypotensive activities of Amiloride.Approved
AminoglutethimideThe serum concentration of Aripiprazole can be decreased when it is combined with Aminoglutethimide.Approved, Investigational
AmiodaroneThe serum concentration of Aripiprazole can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Aripiprazole.Approved
AmlodipineAripiprazole may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Amperozide.Experimental
AmphetamineAripiprazole may decrease the stimulatory activities of Amphetamine.Approved, Illicit
Amphotericin BAripiprazole may increase the hypotensive activities of Amphotericin B.Approved, Investigational
Amyl NitriteAripiprazole may increase the hypotensive activities of Amyl Nitrite.Approved
AnagrelideAripiprazole may increase the QTc-prolonging activities of Anagrelide.Approved
ApomorphineAripiprazole may increase the hypotensive activities of Apomorphine.Approved, Investigational
ApraclonidineAripiprazole may increase the hypotensive activities of Apraclonidine.Approved
AprepitantThe serum concentration of Aripiprazole can be increased when it is combined with Aprepitant.Approved, Investigational
ArmodafinilThe serum concentration of Aripiprazole can be decreased when it is combined with Armodafinil.Approved, Investigational
ArotinololAripiprazole may increase the hypotensive activities of Arotinolol.Approved, Investigational
Arsenic trioxideAripiprazole may increase the hypotensive activities of Arsenic trioxide.Approved, Investigational
ArtemetherThe serum concentration of Aripiprazole can be decreased when it is combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Articaine.Approved
AsenapineAripiprazole may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirThe serum concentration of Aripiprazole can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololAripiprazole may increase the hypotensive activities of Atenolol.Approved
AtomoxetineThe serum concentration of Aripiprazole can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Aripiprazole can be decreased when it is combined with Atorvastatin.Approved
AvasimibeThe serum concentration of Aripiprazole can be decreased when it is combined with Avasimibe.Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Azaperone.Investigational, Vet Approved
AzatadineThe serum concentration of Aripiprazole can be decreased when it is combined with Azatadine.Approved
AzelastineAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Azilsartan medoxomilAripiprazole may increase the hypotensive activities of Azilsartan medoxomil.Approved
AzithromycinAripiprazole may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Baclofen.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Aripiprazole.Investigational
BarbitalThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Barbital.Illicit
BarnidipineAripiprazole may increase the hypotensive activities of Barnidipine.Approved
Beclomethasone dipropionateThe serum concentration of Aripiprazole can be decreased when it is combined with Beclomethasone dipropionate.Approved, Investigational
BedaquilineAripiprazole may increase the QTc-prolonging activities of Bedaquiline.Approved
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Aripiprazole.Investigational
BenazeprilAripiprazole may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideAripiprazole may increase the hypotensive activities of Bendroflumethiazide.Approved
BenperidolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Benzocaine.Approved
BenzphetamineAripiprazole may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Benzyl alcohol.Approved
BepridilAripiprazole may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololAripiprazole may increase the hypotensive activities of Betaxolol.Approved
BexaroteneThe serum concentration of Aripiprazole can be decreased when it is combined with Bexarotene.Approved, Investigational
BisoprololAripiprazole may increase the hypotensive activities of Bisoprolol.Approved
BoceprevirThe serum concentration of Aripiprazole can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe serum concentration of Aripiprazole can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Aripiprazole can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumAripiprazole may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Brexpiprazole.Approved
BrimonidineAripiprazole may increase the hypotensive activities of Brimonidine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Bromazepam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Bromisoval.Experimental
BromocriptineAripiprazole may increase the hypotensive activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Brotizolam.Approved, Investigational, Withdrawn
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Aripiprazole.Investigational, Withdrawn
BumetanideAripiprazole may increase the hypotensive activities of Bumetanide.Approved
BupivacaineAripiprazole may increase the hypotensive activities of Bupivacaine.Approved, Investigational
BuprenorphineAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Aripiprazole can be increased when it is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Aripiprazole.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Aripiprazole.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Aripiprazole.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Aripiprazole.Approved
CalcitriolThe serum concentration of Aripiprazole can be decreased when it is combined with Calcitriol.Approved, Nutraceutical
CanagliflozinAripiprazole may increase the hypotensive activities of Canagliflozin.Approved
Candesartan cilexetilAripiprazole may increase the hypotensive activities of Candesartan cilexetil.Approved
CanertinibThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Canertinib.Investigational
CaptoprilAripiprazole may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe serum concentration of Aripiprazole can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbetocinAripiprazole may increase the hypotensive activities of Carbetocin.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Carbinoxamine.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Aripiprazole.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Carisoprodol.Approved
CarteololAripiprazole may increase the hypotensive activities of Carteolol.Approved
CarvedilolAripiprazole may increase the hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Aripiprazole.Experimental
CefradineThe serum concentration of Aripiprazole can be decreased when it is combined with Cefradine.Approved
CelecoxibThe serum concentration of Aripiprazole can be increased when it is combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Aripiprazole can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Aripiprazole can be decreased when it is combined with Cerivastatin.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Aripiprazole.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Chloroprocaine.Approved
ChloroquineThe serum concentration of Aripiprazole can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideAripiprazole may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Chlorphenamine.Approved
ChlorphenesinThe serum concentration of Aripiprazole can be decreased when it is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorphentermineAripiprazole may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe serum concentration of Aripiprazole can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Aripiprazole.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidoneAripiprazole may increase the hypotensive activities of Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Chlorzoxazone.Approved
CholecalciferolThe serum concentration of Aripiprazole can be increased when it is combined with Cholecalciferol.Approved, Nutraceutical
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Aripiprazole.Experimental
CilazaprilAripiprazole may increase the hypotensive activities of Cilazapril.Approved
CilnidipineAripiprazole may increase the hypotensive activities of Cilnidipine.Approved, Investigational
CimetidineThe serum concentration of Aripiprazole can be increased when it is combined with Cimetidine.Approved
CinacalcetThe serum concentration of Aripiprazole can be increased when it is combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Cinchocaine.Approved, Vet Approved
CiprofloxacinAripiprazole may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideAripiprazole may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Aripiprazole can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Aripiprazole can be increased when it is combined with Clarithromycin.Approved
ClemastineThe serum concentration of Aripiprazole can be increased when it is combined with Clemastine.Approved
ClevidipineThe serum concentration of Aripiprazole can be decreased when it is combined with Clevidipine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Clidinium.Approved
ClobazamThe serum concentration of Aripiprazole can be decreased when it is combined with Clobazam.Approved, Illicit
ClofarabineAripiprazole may increase the hypotensive activities of Clofarabine.Approved, Investigational
ClofibrateThe serum concentration of Aripiprazole can be decreased when it is combined with Clofibrate.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with clomethiazole.Investigational
ClomipramineThe serum concentration of Aripiprazole can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Clonazepam.Approved, Illicit
ClonidineAripiprazole may increase the hypotensive activities of Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Aripiprazole.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Clothiapine.Experimental
ClotrimazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Aripiprazole can be decreased when it is combined with Clozapine.Approved
CobicistatThe serum concentration of Aripiprazole can be increased when it is combined with Cobicistat.Approved
CocaineThe serum concentration of Aripiprazole can be increased when it is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Aripiprazole.Approved, Illicit
ColchicineThe serum concentration of Aripiprazole can be decreased when it is combined with Colchicine.Approved
ConivaptanThe serum concentration of Aripiprazole can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe serum concentration of Aripiprazole can be increased when it is combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Aripiprazole.Approved
CyclophosphamideThe serum concentration of Aripiprazole can be decreased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Aripiprazole can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Aripiprazole can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dantrolene.Approved
DapagliflozinAripiprazole may increase the hypotensive activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dapoxetine.Investigational
DarifenacinThe serum concentration of Aripiprazole can be increased when it is combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Aripiprazole can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Aripiprazole can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Aripiprazole can be decreased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Aripiprazole can be decreased when it is combined with Deferasirox.Approved, Investigational
DelafloxacinThe serum concentration of Aripiprazole can be decreased when it is combined with Delafloxacin.Approved, Investigational
DelavirdineThe serum concentration of Aripiprazole can be increased when it is combined with Delavirdine.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Aripiprazole.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Deramciclane.Investigational
DesfluraneAripiprazole may increase the hypotensive activities of Desflurane.Approved
DesipramineThe serum concentration of Aripiprazole can be increased when it is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe serum concentration of Aripiprazole can be decreased when it is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Aripiprazole can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dexbrompheniramine.Approved
DexmedetomidineAripiprazole may increase the hypotensive activities of Dexmedetomidine.Approved, Vet Approved
DextroamphetamineAripiprazole may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Aripiprazole.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe serum concentration of Aripiprazole can be decreased when it is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Aripiprazole.Approved, Illicit, Vet Approved
DiclofenamideAripiprazole may increase the hypotensive activities of Diclofenamide.Approved
DicloxacillinThe serum concentration of Aripiprazole can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Diethyl ether.Experimental
DiethylpropionAripiprazole may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe serum concentration of Aripiprazole can be increased when it is combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe serum concentration of Aripiprazole can be increased when it is combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dimenhydrinate.Approved
DinutuximabAripiprazole may increase the hypotensive activities of Dinutuximab.Approved
DiphenhydramineThe serum concentration of Aripiprazole can be increased when it is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Aripiprazole.Approved, Illicit
DipyridamoleAripiprazole may increase the hypotensive activities of Dipyridamole.Approved
DisopyramideAripiprazole may increase the QTc-prolonging activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dixyrazine.Experimental
DofetilideAripiprazole may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronAripiprazole may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneAripiprazole may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Doramectin.Vet Approved
DosulepinThe serum concentration of Aripiprazole can be increased when it is combined with Dosulepin.Approved
DoxazosinAripiprazole may increase the hypotensive activities of Doxazosin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Doxepin.Approved
DoxycyclineThe serum concentration of Aripiprazole can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Aripiprazole is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved, Illicit
DronedaroneThe serum concentration of Aripiprazole can be increased when it is combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved, Vet Approved
DrospirenoneThe serum concentration of Aripiprazole can be decreased when it is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Drotebanol.Experimental, Illicit
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Aripiprazole.Approved
DuloxetineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Aripiprazole can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineAripiprazole may increase the hypotensive activities of Efonidipine.Approved, Investigational
EletriptanThe serum concentration of Aripiprazole can be decreased when it is combined with Eletriptan.Approved, Investigational
EliglustatThe serum concentration of Aripiprazole can be increased when it is combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Eltanolone.Investigational
EmpagliflozinAripiprazole may increase the hypotensive activities of Empagliflozin.Approved
EnalaprilAripiprazole may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatAripiprazole may increase the hypotensive activities of Enalaprilat.Approved
EnasidenibThe serum concentration of Aripiprazole can be decreased when it is combined with Enasidenib.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Aripiprazole can be decreased when it is combined with Enzalutamide.Approved
EplerenoneAripiprazole may increase the hypotensive activities of Eplerenone.Approved
EpoprostenolAripiprazole may increase the hypotensive activities of Epoprostenol.Approved
EprosartanAripiprazole may increase the hypotensive activities of Eprosartan.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Aripiprazole.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Aripiprazole.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Aripiprazole.Approved
ErythromycinThe serum concentration of Aripiprazole can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramAripiprazole may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Aripiprazole can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololAripiprazole may increase the hypotensive activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Aripiprazole.Approved, Illicit
EstradiolThe serum concentration of Aripiprazole can be decreased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Aripiprazole.Approved
Etacrynic acidAripiprazole may increase the hypotensive activities of Etacrynic acid.Approved
EthanolThe serum concentration of Aripiprazole can be decreased when it is combined with Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Etoperidone.Withdrawn
EtoposideThe serum concentration of Aripiprazole can be decreased when it is combined with Etoposide.Approved
EtorphineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Aripiprazole can be decreased when it is combined with Etravirine.Approved
ExemestaneThe serum concentration of Aripiprazole can be decreased when it is combined with Exemestane.Approved, Investigational
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Aripiprazole.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ezogabine.Approved
FelbamateThe serum concentration of Aripiprazole can be decreased when it is combined with Felbamate.Approved
FelodipineAripiprazole may increase the hypotensive activities of Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamAripiprazole may increase the hypotensive activities of Fenoldopam.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Aripiprazole.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Aripiprazole.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fexofenadine.Approved
FimasartanAripiprazole may increase the hypotensive activities of Fimasartan.Approved, Investigational
FlecainideAripiprazole may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fluanisone.Experimental
FlucloxacillinThe serum concentration of Aripiprazole can be decreased when it is combined with Flucloxacillin.Approved, Investigational
FluconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Flunitrazepam.Approved, Illicit
FluorometholoneThe serum concentration of Aripiprazole can be decreased when it is combined with Fluorometholone.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Aripiprazole.Approved, Vet Approved
FlupentixolAripiprazole may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Aripiprazole.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Aripiprazole.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fluticasone propionate.Approved
FluvastatinThe serum concentration of Aripiprazole can be decreased when it is combined with Fluvastatin.Approved
FluvoxamineThe serum concentration of Aripiprazole can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Aripiprazole can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Aripiprazole can be decreased when it is combined with Fosaprepitant.Approved
FosinoprilAripiprazole may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinThe serum concentration of Aripiprazole can be decreased when it is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Fospropofol.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Aripiprazole.Approved, Investigational
FurosemideAripiprazole may increase the hypotensive activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Aripiprazole can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Aripiprazole.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Gabapentin Enacarbil.Approved
Gadobenic acidAripiprazole may increase the QTc-prolonging activities of Gadobenic acid.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GemfibrozilThe serum concentration of Aripiprazole can be decreased when it is combined with Gemfibrozil.Approved
GemifloxacinAripiprazole may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepefrineAripiprazole may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Gepirone.Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Aripiprazole.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Aripiprazole.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Aripiprazole.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Aripiprazole.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Aripiprazole.Approved, Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Glutethimide.Approved, Illicit
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Aripiprazole.Approved
GoserelinAripiprazole may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronAripiprazole may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GriseofulvinThe serum concentration of Aripiprazole can be decreased when it is combined with Griseofulvin.Approved, Vet Approved
GuanethidineThe serum concentration of Aripiprazole can be decreased when it is combined with Guanethidine.Approved
GuanfacineAripiprazole may increase the hypotensive activities of Guanfacine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Aripiprazole.Investigational
HalazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolAripiprazole may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneAripiprazole may increase the hypotensive activities of Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Hexobarbital.Approved
HydralazineAripiprazole may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideAripiprazole may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortamateThe serum concentration of Aripiprazole can be decreased when it is combined with Hydrocortamate.Approved
HydrocortisoneThe serum concentration of Aripiprazole can be decreased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideAripiprazole may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Aripiprazole.Approved, Illicit
HydroxyamphetamineAripiprazole may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved
IbutilideAripiprazole may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Aripiprazole can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of Aripiprazole can be decreased when it is combined with Ifosfamide.Approved
IloperidoneAripiprazole may increase the QTc-prolonging activities of Iloperidone.Approved
IloprostAripiprazole may increase the hypotensive activities of Iloprost.Approved, Investigational
ImatinibThe serum concentration of Aripiprazole can be increased when it is combined with Imatinib.Approved
ImidaprilAripiprazole may increase the hypotensive activities of Imidapril.Investigational
ImipramineThe serum concentration of Aripiprazole can be increased when it is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Indalpine.Investigational, Withdrawn
IndapamideAripiprazole may increase the hypotensive activities of Indapamide.Approved
IndinavirThe serum concentration of Aripiprazole can be increased when it is combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Indiplon.Investigational
IndoraminAripiprazole may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Aripiprazole.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Aripiprazole.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Aripiprazole.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Aripiprazole.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Aripiprazole.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Aripiprazole.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Aripiprazole.Approved
Iofetamine I-123Aripiprazole may decrease the stimulatory activities of Iofetamine I-123.Approved
IrbesartanAripiprazole may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsavuconazoniumThe serum concentration of Aripiprazole can be decreased when it is combined with Isavuconazonium.Approved, Investigational
IsocarboxazidAripiprazole may increase the hypotensive activities of Isocarboxazid.Approved
IsofluraneAripiprazole may increase the hypotensive activities of Isoflurane.Approved, Vet Approved
IsoniazidThe serum concentration of Aripiprazole can be increased when it is combined with Isoniazid.Approved
Isosorbide DinitrateAripiprazole may increase the hypotensive activities of Isosorbide Dinitrate.Approved
Isosorbide MononitrateAripiprazole may increase the hypotensive activities of Isosorbide Mononitrate.Approved
IsoxsuprineAripiprazole may increase the hypotensive activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe serum concentration of Aripiprazole can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Aripiprazole can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Aripiprazole.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolAripiprazole may increase the hypotensive activities of Labetalol.Approved
LacidipineAripiprazole may increase the hypotensive activities of Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Lamotrigine.Approved, Investigational
LansoprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Lansoprazole.Approved, Investigational
LenvatinibAripiprazole may increase the QTc-prolonging activities of Lenvatinib.Approved
LercanidipineAripiprazole may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LeuprolideAripiprazole may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Levetiracetam.Approved, Investigational
LevobunololAripiprazole may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineAripiprazole may increase the hypotensive activities of Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Levocetirizine.Approved
LevodopaAripiprazole may increase the hypotensive activities of Levodopa.Approved
LevofloxacinAripiprazole may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Aripiprazole.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Aripiprazole.Approved
LevosimendanAripiprazole may increase the hypotensive activities of Levosimendan.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Aripiprazole.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Aripiprazole.Approved, Investigational
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Aripiprazole.Approved
LisdexamfetamineAripiprazole may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilAripiprazole may increase the hypotensive activities of Lisinopril.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Aripiprazole.Approved
LofentanilThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Lofentanil.Illicit
LofexidineAripiprazole may increase the hypotensive activities of Lofexidine.Approved, Investigational
LopinavirThe serum concentration of Aripiprazole can be increased when it is combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Loprazolam.Experimental
LoratadineThe serum concentration of Aripiprazole can be decreased when it is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Aripiprazole.Approved
LorcaserinThe serum concentration of Aripiprazole can be increased when it is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Lormetazepam.Approved
LosartanAripiprazole may increase the hypotensive activities of Losartan.Approved
LovastatinThe serum concentration of Aripiprazole can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Aripiprazole.Approved
LuliconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Aripiprazole can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Aripiprazole can be decreased when it is combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved, Vet Approved
ManidipineThe serum concentration of Aripiprazole can be increased when it is combined with Manidipine.Approved, Investigational
MannitolAripiprazole may increase the hypotensive activities of Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Mebicar.Experimental
MecamylamineAripiprazole may increase the hypotensive activities of Mecamylamine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Medetomidine.Vet Approved
Medroxyprogesterone acetateThe serum concentration of Aripiprazole can be decreased when it is combined with Medroxyprogesterone acetate.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Melperone.Approved, Investigational
MephedroneAripiprazole may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineAripiprazole may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Aripiprazole.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Meptazinol.Experimental
MequitazineAripiprazole may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Mesoridazine.Approved, Investigational
MetamizoleThe serum concentration of Aripiprazole can be decreased when it is combined with Metamizole.Investigational, Withdrawn
MetaxaloneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Metaxalone.Approved
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Aripiprazole.Approved
MethadoneMethadone may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineAripiprazole may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methaqualone.Illicit, Withdrawn
MethazolamideAripiprazole may increase the hypotensive activities of Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Aripiprazole.Approved
MethotrimeprazineAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineAripiprazole may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methsuximide.Approved
MethyclothiazideAripiprazole may increase the hypotensive activities of Methyclothiazide.Approved
MethyldopaAripiprazole may increase the hypotensive activities of Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methylecgonine.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methylphenobarbital.Approved
MetipranololAripiprazole may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Aripiprazole.Approved, Investigational
MetolazoneAripiprazole may increase the hypotensive activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Aripiprazole.Approved, Investigational
MetyraponeThe serum concentration of Aripiprazole can be decreased when it is combined with Metyrapone.Approved
MetyrosineAripiprazole may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Aripiprazole.Approved, Illicit
MidomafetamineAripiprazole may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MidostaurinThe serum concentration of Aripiprazole can be increased when it is combined with Midostaurin.Approved
MifepristoneMifepristone may increase the QTc-prolonging activities of Aripiprazole.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Aripiprazole.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Aripiprazole.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Aripiprazole.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved, Investigational
MinoxidilAripiprazole may increase the hypotensive activities of Minoxidil.Approved
MirabegronThe serum concentration of Aripiprazole can be increased when it is combined with Mirabegron.Approved
MirtazapineAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Aripiprazole.Approved, Investigational
MitotaneThe serum concentration of Aripiprazole can be decreased when it is combined with Mitotane.Approved
MMDAAripiprazole may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Aripiprazole.Approved
ModafinilThe serum concentration of Aripiprazole can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilAripiprazole may increase the hypotensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Molindone.Approved
MorphineAripiprazole may increase the hypotensive activities of Morphine.Approved, Investigational
MoxifloxacinAripiprazole may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineAripiprazole may increase the hypotensive activities of Moxonidine.Approved, Investigational
MyrrhThe serum concentration of Aripiprazole can be decreased when it is combined with Myrrh.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved, Investigational
NadololAripiprazole may increase the hypotensive activities of Nadolol.Approved
NafcillinThe serum concentration of Aripiprazole can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Aripiprazole.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Aripiprazole.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Aripiprazole.Approved, Investigational
NebivololAripiprazole may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Aripiprazole can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Aripiprazole can be increased when it is combined with Nelfinavir.Approved
NesiritideAripiprazole may increase the hypotensive activities of Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Aripiprazole can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Aripiprazole can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Aripiprazole can be decreased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Aripiprazole can be decreased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Aripiprazole can be increased when it is combined with Nilotinib.Approved, Investigational
NilvadipineAripiprazole may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipineAripiprazole may increase the hypotensive activities of Nimodipine.Approved
NisoldipineAripiprazole may increase the hypotensive activities of Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Nitrazepam.Approved
NitrendipineAripiprazole may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideAripiprazole may increase the hypotensive activities of Nitric Oxide.Approved
NitroglycerinAripiprazole may increase the hypotensive activities of Nitroglycerin.Approved, Investigational
NitroprussideAripiprazole may increase the hypotensive activities of Nitroprusside.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Nitrous oxide.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Norflurane.Investigational
NorgestimateThe serum concentration of Aripiprazole can be decreased when it is combined with Norgestimate.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Aripiprazole.Approved
ObinutuzumabAripiprazole may increase the hypotensive activities of Obinutuzumab.Approved
OfloxacinAripiprazole may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Aripiprazole.Approved, Investigational
OlaparibThe serum concentration of Aripiprazole can be increased when it is combined with Olaparib.Approved
OlmesartanAripiprazole may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Olopatadine.Approved
OmeprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronAripiprazole may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Opium.Approved, Illicit
OritavancinThe serum concentration of Aripiprazole can be decreased when it is combined with Oritavancin.Approved, Investigational
OrlistatThe serum concentration of Aripiprazole can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Aripiprazole can be decreased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Aripiprazole.Approved
OxcarbazepineThe serum concentration of Aripiprazole can be decreased when it is combined with Oxcarbazepine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Oxethazaine.Approved, Investigational
OxiconazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Oxiconazole.Approved
OxprenololAripiprazole may increase the hypotensive activities of Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Aripiprazole.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Aripiprazole.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Aripiprazole can be decreased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Aripiprazole can be increased when it is combined with Palbociclib.Approved
PaliperidoneAripiprazole may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatThe serum concentration of Aripiprazole can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Pantoprazole.Approved
PapaverineAripiprazole may increase the hypotensive activities of Papaverine.Approved
ParaldehydeAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Aripiprazole.Approved, Investigational
PazopanibAripiprazole may increase the QTc-prolonging activities of Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Aripiprazole can be decreased when it is combined with Peginterferon alfa-2b.Approved
PegvisomantThe serum concentration of Aripiprazole can be decreased when it is combined with Pegvisomant.Approved
PenbutololAripiprazole may increase the hypotensive activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Penfluridol.Experimental
PentamidineAripiprazole may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Aripiprazole.Approved, Vet Approved
PentobarbitalThe serum concentration of Aripiprazole can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved
PerazineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Perazine.Investigational
PerflutrenAripiprazole may increase the QTc-prolonging activities of Perflutren.Approved
PerindoprilAripiprazole may increase the hypotensive activities of Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Aripiprazole.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Aripiprazole.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Phenazocine.Experimental
PhenelzineAripiprazole may increase the hypotensive activities of Phenelzine.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Aripiprazole.Approved, Investigational, Withdrawn
PhenibutThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Phenibut.Experimental
PhenobarbitalThe serum concentration of Aripiprazole can be decreased when it is combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Phenoperidine.Experimental
PhenoxybenzamineAripiprazole may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Phenoxyethanol.Approved
PhentermineAripiprazole may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhentolamineAripiprazole may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazoneThe serum concentration of Aripiprazole can be decreased when it is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe serum concentration of Aripiprazole can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideAripiprazole may increase the QTc-prolonging activities of Pimozide.Approved
PindololAripiprazole may increase the hypotensive activities of Pindolol.Approved
PioglitazoneThe serum concentration of Aripiprazole can be decreased when it is combined with Pioglitazone.Approved, Investigational
PipamperoneAripiprazole may increase the hypotensive activities of Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Pipotiazine.Approved, Investigational
PiribedilThe therapeutic efficacy of Piribedil can be decreased when used in combination with Aripiprazole.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Pomalidomide.Approved
PosaconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleAripiprazole may increase the sedative activities of Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Aripiprazole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Prazepam.Approved, Illicit
PrazosinAripiprazole may increase the hypotensive activities of Prazosin.Approved
PrednisoneThe serum concentration of Aripiprazole can be decreased when it is combined with Prednisone.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Aripiprazole.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Prilocaine.Approved
PrimaquineAripiprazole may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe serum concentration of Aripiprazole can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Aripiprazole can be decreased when it is combined with Probenecid.Approved
ProcainamideAripiprazole may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Aripiprazole.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Aripiprazole.Approved, Vet Approved
ProgesteroneThe serum concentration of Aripiprazole can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazineThe serum concentration of Aripiprazole can be increased when it is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Aripiprazole.Approved
PropafenoneAripiprazole may increase the QTc-prolonging activities of Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Proparacaine.Approved, Vet Approved
PropofolAripiprazole may increase the hypotensive activities of Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Propoxycaine.Approved
PropranololAripiprazole may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Aripiprazole is combined with PSD502.Investigational
PseudoephedrineAripiprazole may decrease the stimulatory activities of Pseudoephedrine.Approved
PyridostigmineThe serum concentration of Aripiprazole can be decreased when it is combined with Pyridostigmine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Quazepam.Approved, Illicit
QuetiapineAripiprazole may increase the hypotensive activities of Quetiapine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Aripiprazole.Approved
QuinaprilAripiprazole may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinidineThe serum concentration of Aripiprazole can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Aripiprazole can be decreased when it is combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ramelteon.Approved, Investigational
RamiprilAripiprazole may increase the hypotensive activities of Ramipril.Approved
RanolazineThe serum concentration of Aripiprazole can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineAripiprazole may increase the hypotensive activities of Rasagiline.Approved
RemifentanilAripiprazole may increase the hypotensive activities of Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Remoxipride.Approved, Withdrawn
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Aripiprazole.Approved, Investigational
ReserpineThe serum concentration of Aripiprazole can be decreased when it is combined with Reserpine.Approved, Investigational
RifabutinThe serum concentration of Aripiprazole can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Aripiprazole can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Aripiprazole can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Aripiprazole can be decreased when it is combined with Rifaximin.Approved, Investigational
RilpivirineThe serum concentration of Aripiprazole can be decreased when it is combined with Rilpivirine.Approved
RiociguatAripiprazole may increase the hypotensive activities of Riociguat.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Aripiprazole.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ritanserin.Investigational
RitobegronAripiprazole may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Aripiprazole.Approved
RofecoxibThe serum concentration of Aripiprazole can be decreased when it is combined with Rofecoxib.Investigational, Withdrawn
RolapitantThe serum concentration of Aripiprazole can be increased when it is combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Romifidine.Vet Approved
RopiniroleAripiprazole may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineAripiprazole may increase the hypotensive activities of Ropivacaine.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Aripiprazole.Approved, Investigational
RotigotineAripiprazole may increase the sedative activities of Rotigotine.Approved
RufinamideThe serum concentration of Aripiprazole can be decreased when it is combined with Rufinamide.Approved
SacubitrilAripiprazole may increase the hypotensive activities of Sacubitril.Approved
SaquinavirThe serum concentration of Aripiprazole can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Aripiprazole.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Aripiprazole.Approved, Vet Approved
SelegilineAripiprazole may increase the hypotensive activities of Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Sepranolone.Investigational
SeratrodastThe serum concentration of Aripiprazole can be decreased when it is combined with Seratrodast.Approved
SertindoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Aripiprazole.Approved
SevofluraneAripiprazole may increase the hypotensive activities of Sevoflurane.Approved, Vet Approved
SildenafilThe serum concentration of Aripiprazole can be increased when it is combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Aripiprazole can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Aripiprazole can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Aripiprazole can be decreased when it is combined with Simvastatin.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Aripiprazole.Approved, Investigational
Sodium NitriteAripiprazole may increase the hypotensive activities of Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Aripiprazole.Investigational
SotalolAripiprazole may increase the hypotensive activities of Sotalol.Approved
SpironolactoneAripiprazole may increase the hypotensive activities of Spironolactone.Approved
St. John's WortThe serum concentration of Aripiprazole can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Aripiprazole can be increased when it is combined with Stiripentol.Approved
StreptokinaseAripiprazole may increase the hypotensive activities of Streptokinase.Approved, Investigational
SufentanilAripiprazole may increase the hypotensive activities of Sufentanil.Approved, Investigational
SulfinpyrazoneThe serum concentration of Aripiprazole can be decreased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe serum concentration of Aripiprazole can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Aripiprazole.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Aripiprazole.Approved, Investigational
SuvorexantAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamoxifenThe serum concentration of Aripiprazole can be decreased when it is combined with Tamoxifen.Approved
TamsulosinAripiprazole may increase the hypotensive activities of Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Aripiprazole.Approved
TelaprevirThe serum concentration of Aripiprazole can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelavancinAripiprazole may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe serum concentration of Aripiprazole can be increased when it is combined with Telithromycin.Approved
TelmisartanAripiprazole may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Aripiprazole.Approved
TemozolomideThe serum concentration of Aripiprazole can be decreased when it is combined with Temozolomide.Approved, Investigational
TerazosinAripiprazole may increase the hypotensive activities of Terazosin.Approved
TerbinafineThe serum concentration of Aripiprazole can be increased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Aripiprazole can be decreased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Aripiprazole can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Aripiprazole can be decreased when it is combined with Testosterone.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Aripiprazole.Approved
TetracaineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tetrodotoxin.Investigational
ThalidomideThe serum concentration of Aripiprazole can be decreased when it is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Thiopental.Approved, Vet Approved
ThioridazineThe serum concentration of Aripiprazole can be increased when it is combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tiapride.Approved, Investigational
TiclopidineThe serum concentration of Aripiprazole can be increased when it is combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tilidine.Experimental
TimololAripiprazole may increase the hypotensive activities of Timolol.Approved
TipranavirThe serum concentration of Aripiprazole can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineAripiprazole may increase the hypotensive activities of Tizanidine.Approved
TocilizumabThe serum concentration of Aripiprazole can be decreased when it is combined with Tocilizumab.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Aripiprazole.Approved
TolazolineAripiprazole may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Aripiprazole.Approved
TolcaponeAripiprazole may increase the hypotensive activities of Tolcapone.Approved, Withdrawn
TopiramateThe serum concentration of Aripiprazole can be decreased when it is combined with Topiramate.Approved
TopotecanThe serum concentration of Aripiprazole can be decreased when it is combined with Topotecan.Approved, Investigational
TorasemideAripiprazole may increase the hypotensive activities of Torasemide.Approved
ToremifeneAripiprazole may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Aripiprazole.Approved, Investigational
TrametinibThe serum concentration of Aripiprazole can be decreased when it is combined with Trametinib.Approved
TrandolaprilAripiprazole may increase the hypotensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe serum concentration of Aripiprazole can be increased when it is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Trazodone.Approved, Investigational
TretinoinAripiprazole may increase the hypotensive activities of Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneAripiprazole may increase the hypotensive activities of Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Aripiprazole.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Aripiprazole.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Triprolidine.Approved
TroglitazoneThe serum concentration of Aripiprazole can be decreased when it is combined with Troglitazone.Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Valproic Acid.Approved, Investigational
ValsartanAripiprazole may increase the hypotensive activities of Valsartan.Approved, Investigational
VandetanibAripiprazole may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibThe serum concentration of Aripiprazole can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe serum concentration of Aripiprazole can be increased when it is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Veralipride.Experimental
VerapamilThe serum concentration of Aripiprazole can be increased when it is combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Aripiprazole.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Aripiprazole.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Vinyl ether.Experimental
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Aripiprazole.Approved, Investigational
VoriconazoleThe serum concentration of Aripiprazole can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Aripiprazole.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Zimelidine.Withdrawn
ZiprasidoneThe serum concentration of Aripiprazole can be increased when it is combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Aripiprazole.Approved, Investigational
ZolpidemAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Aripiprazole.Approved
ZotepineThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Zotepine.Approved, Investigational
ZuclopenthixolAripiprazole may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol (possible additive effect to CNS).
  • Food has no significant effect on absorption.
  • Take without regard to meals.

References

Synthesis Reference
US5006528
General References
Not Available
External Links
Human Metabolome Database
HMDB05042
KEGG Drug
D01164
KEGG Compound
C12564
PubChem Compound
60795
PubChem Substance
46505745
ChemSpider
54790
BindingDB
50130293
ChEBI
31236
ChEMBL
CHEMBL1112
Therapeutic Targets Database
DAP000076
PharmGKB
PA10026
IUPHAR
34
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Aripiprazole
ATC Codes
N05AX12 — Aripiprazole
AHFS Codes
  • 28:16.08.04 — Atypical Antipsychotics
FDA label
Download (262 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingSupportive CareSchizophrenic Disorders1
1CompletedNot AvailableBipolar Disorder (BD)1
1CompletedNot AvailableDepressive Disorders1
1CompletedNot AvailableHealthy Volunteers2
1CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections2
1CompletedNot AvailableSchizophrenic Disorders1
1CompletedBasic ScienceAlzheimer's Disease (AD)1
1CompletedBasic ScienceBipolar Disorder (BD) / Depressive Disorders / Psychotic Disorder NOS / Schizophrenic Disorders1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceSchizophrenic Disorders1
1CompletedTreatmentCocaine-Related Disorders1
1CompletedTreatmentNervous System Diseases / Psychiatric Disorder NOS / Schizophrenic Disorders1
1CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
1CompletedTreatmentSchizophrenic Disorders5
1Not Yet RecruitingOtherSchizophrenic Disorders1
1RecruitingNot AvailableAntipsychotics / Immunoassay1
1RecruitingOtherSchizophrenic Disorders1
1RecruitingTreatmentHealthy Male Adults1
1Unknown StatusTreatmentAmphetamine-Related Disorders1
1, 2RecruitingBasic ScienceSchizophrenic Disorders1
2CompletedTreatmentAcute Schizophrenia / Schizoaffective Disorders1
2CompletedTreatmentAlcohol Dependence1
2CompletedTreatmentAsperger's Disorder / Autism, Early Infantile / Pervasive Developmental Disorder NOS1
2CompletedTreatmentAsperger's Disorder / Pervasive Developmental Disorder NOS1
2CompletedTreatmentAsperger's Syndrome / Autism Spectrum Conditions/Disorders / Autistic Disorder1
2CompletedTreatmentAutism, Early Infantile1
2CompletedTreatmentBehavioral Problems Associated With Fragile X Syndrome / Fragile X Syndrome (FXS)1
2CompletedTreatmentBipolar I Disorder / Major Depressive Disorder (MDD) / Schizophrenic Disorders1
2CompletedTreatmentCocaine Abuse1
2CompletedTreatmentDepression1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Substance Abuse1
2CompletedTreatmentMania / Schizophrenic Disorders1
2CompletedTreatmentPTSD1
2CompletedTreatmentSchizophrenic Disorders3
2RecruitingTreatmentAutism Spectrum Conditions/Disorders1
2TerminatedTreatmentAttention Deficit Hyperactivity Disorder (ADHD)1
2TerminatedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
2Unknown StatusTreatmentDependence, Cocaine / Schizophrenic Disorders1
2WithdrawnTreatmentBipolar 1 Disorder / Nervous System Diseases / Psychiatric Disorder NOS / Schizophrenic Disorders1
2, 3CompletedTreatmentAlcohol Dependence1
2, 3CompletedTreatmentPsychosis / Schizophrenic Disorders1
2, 3CompletedTreatmentSchizophrenic Disorders2
2, 3TerminatedTreatmentSchizophrenic Disorders1
2, 3WithdrawnTreatmentDiabetes Mellitus (DM)1
3Active Not RecruitingDiagnosticMajor Depressive Disorder (MDD)1
3Active Not RecruitingTreatmentSchizophrenic Disorders1
3CompletedNot AvailableSchizophrenia and Schizoaffective Disorder1
3CompletedDiagnosticMajor Depressive Disorder (MDD)1
3CompletedPreventionBipolar Disorder (BD)1
3CompletedTreatmentAlcohol Dependence1
3CompletedTreatmentAlzheimer's Disease (AD)2
3CompletedTreatmentAlzheimer's Disease (AD) / Dementias1
3CompletedTreatmentAutistic Disorder4
3CompletedTreatmentAutistic Disorder / Behavioral Symptoms2
3CompletedTreatmentBipolar Disorder (BD)9
3CompletedTreatmentBipolar Disorder (BD) / Schizophrenic Disorders1
3CompletedTreatmentBipolar Disorder Mania1
3CompletedTreatmentBipolar I1
3CompletedTreatmentBipolar I Disorder6
3CompletedTreatmentBody Weight Changes / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders1
3CompletedTreatmentChronic Motor or Vocal Tic Disorder / Tourette's Disorder1
3CompletedTreatmentDementia, Alzheimer Type1
3CompletedTreatmentMajor Depressive Disorder (MDD)6
3CompletedTreatmentPervasive Developmental Disorder NOS1
3CompletedTreatmentPostpartum Depression1
3CompletedTreatmentPosttraumatic Stress Disorders1
3CompletedTreatmentPsychotic Depression1
3CompletedTreatmentPsychotic Disorder NOS / Schizophrenic Disorders1
3CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders2
3CompletedTreatmentSchizophrenia and Schizoaffective Disorder1
3CompletedTreatmentSchizophrenic Disorders20
3CompletedTreatmentTic Disorders / Tourette's Disorder2
3CompletedTreatmentTourette's Disorder3
3Not Yet RecruitingTreatmentSchizophrenic Disorders2
3RecruitingTreatmentAlcohol Abuse / Alcoholism / Bipolar Disorder (BD)1
3RecruitingTreatmentPsychotic Disorder NOS / Schizophrenic Disorders1
3RecruitingTreatmentSchizophrenic Disorders1
3TerminatedTreatmentAcute Depressive Episode / Bipolar Disorder (BD)1
3TerminatedTreatmentAdolescent Schizophrenia / Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features1
3TerminatedTreatmentAgitation Associated With Dementia of the Alzheimer's Type1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
3TerminatedTreatmentBipolar Disorder (BD) / Schizoaffective Disorders / Schizophrenic Disorders1
3TerminatedTreatmentBipolar I Disorder / Metabolic Syndromes / Schizoaffective Disorders / Schizophrenic Disorders1
3TerminatedTreatmentMajor Depressive Disorder (MDD)3
3TerminatedTreatmentSchizophrenic Disorders3
3TerminatedTreatmentTherapy-Resistant Depression1
3Unknown StatusTreatmentAnorexia Nervosa (AN)1
3Unknown StatusTreatmentPsychosis Nos/Other1
3WithdrawnTreatmentBipolar Disorder (BD)1
4CompletedNot AvailableBipolar Disorder (BD) / Schizophrenic Disorders1
4CompletedNot AvailableMoods Disorders / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
4CompletedBasic ScienceCYP3A4 Protein, Human / Cytochrome P-450 CYP2D6 / Pharmacokinetics1
4CompletedBasic ScienceDiabetes Mellitus (DM)2
4CompletedBasic SciencePsychosis / Schizophrenic Disorders1
4CompletedPreventionSchizophrenic Disorders1
4CompletedSupportive CareAutistic Disorder1
4CompletedTreatmentAdhd / Aggressive Behavior / Bipolar Disorder (BD) / Oppositional Defiant Disorder / PDD1
4CompletedTreatmentAlcoholism1
4CompletedTreatmentAlzheimer's Disease (AD) / Dementias / Schizophrenic Disorders1
4CompletedTreatmentAnxiety Disorders / Bipolar Disorder (BD) / Major Depressive Disorder (MDD) / Schizoaffective Disorders / Schizophrenic Disorders / Substance Abuse1
4CompletedTreatmentAttention Deficit Hyperactivity Disorder (ADHD)1
4CompletedTreatmentAttention Deficit Hyperactivity Disorder (ADHD) / Bipolar Disorder (BD)1
4CompletedTreatmentAutism Spectrum Conditions/Disorders1
4CompletedTreatmentBMI >27 kg/m2 / Cardiovascular Disease (CVD) / Hyperlipidemias1
4CompletedTreatmentBipolar Disorder (BD)7
4CompletedTreatmentBipolar Disorder (BD) / Mania1
4CompletedTreatmentBipolar Disorder (BD) / Metabolic Complications1
4CompletedTreatmentBipolar Disorder (BD) / Metabolic Syndromes / Schizoaffective Disorders / Schizophrenic Disorders1
4CompletedTreatmentDSM-IV Schizophrenia / Schizoaffective Disorders1
4CompletedTreatmentDepression, Bipolar2
4CompletedTreatmentEating Disorders1
4CompletedTreatmentFirst Episode Psychosis1
4CompletedTreatmentGeneralized Anxiety Disorder (GAD) / Panic Disorders1
4CompletedTreatmentGilles de la Tourette's Syndrome / Tic Disorders1
4CompletedTreatmentInsulin Resistance / Schizophrenic Disorders1
4CompletedTreatmentIrritability Associated With Autistic Disorder1
4CompletedTreatmentMajor Depressive Disorder (MDD)3
4CompletedTreatmentOppositional Defiant Disorder1
4CompletedTreatmentParkinson's Disease (PD) / Psychosis1
4CompletedTreatmentPsychotic Disorder NOS1
4CompletedTreatmentPsychotic Disorder NOS / Schizophrenic Disorders4
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders5
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders / Social Anxiety Disorder (SAD)1
4CompletedTreatmentSchizophrenic Disorders19
4CompletedTreatmentSchizophrenic Disorders / Type 2 Diabetes Mellitus1
4CompletedTreatmentIdiopathic hyperprolactinemic disorder1
4Enrolling by InvitationTreatmentPsychosis / Psychotic Disorder NOS / Schizophrenic Disorders1
4Enrolling by InvitationTreatmentPsychotic Disorder NOS / Schizophrenic Disorders1
4Not Yet RecruitingTreatmentAcute Schizophrenia Episode1
4Not Yet RecruitingTreatmentDiagnosis and Treatment of Depression1
4Not Yet RecruitingTreatmentMajor Depressive Disorder (MDD) / Treatment Resistant Depression (TRD)1
4Not Yet RecruitingTreatmentSchizophrenic Disorders1
4RecruitingDiagnosticAsthma Bronchial / Asthma: [Nos] or [Attack] / Major Depressive Disorder (MDD)1
4RecruitingOtherAttenuated Psychosis Syndrome1
4RecruitingTreatmentAntipsychotics Weight Gain1
4RecruitingTreatmentMajor Depressive Disorder (MDD)1
4RecruitingTreatmentPsychotic Disorder NOS / Schizophrenic Disorders1
4RecruitingTreatmentSchizophrenic Disorders2
4RecruitingTreatmentTreatment Resistant Major Depressive Disorder / Treatment Resistant Major Depressive Disorder Depression1
4TerminatedNot AvailableHigh Risk MC4R Genotype / Low Risk MC4R Genotype / One Week or Less Antipsychotic Lifetime Exposure1
4TerminatedTreatmentMajor Depressive Disorder (MDD)1
4TerminatedTreatmentMetabolic Syndromes / Schizophrenic Disorders1
4TerminatedTreatmentMethamphetamine Dependence2
4TerminatedTreatmentPediatric Bipolar Disorder1
4TerminatedTreatmentSchizophrenic Disorders2
4TerminatedTreatmentSexual Dysfunctions1
4Unknown StatusTreatmentAutism, Early Infantile1
4Unknown StatusTreatmentBipolar I Disorder1
4Unknown StatusTreatmentBipolar / Schizophrenic Disorders1
4Unknown StatusTreatmentDyskinesia, Drug-Induced1
4Unknown StatusTreatmentDyslipidemias / Idiopathic hyperprolactinemic disorder / Weight gain therapy1
4Unknown StatusTreatmentPsychosis1
4Unknown StatusTreatmentSchizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
4Unknown StatusTreatmentSchizophrenia or Schizoaffective Disorder1
4Unknown StatusTreatmentSchizophrenia, Tardive Dyskinesia, Metabolic Syndrome1
4Unknown StatusTreatmentSchizophrenic Disorders3
4Unknown StatusTreatmentIdiopathic hyperprolactinemic disorder / Sexual Dysfunctions1
4WithdrawnPreventionSchizophrenic Disorders1
4WithdrawnTreatmentDepressive Disorder Not Otherwise Specified (NOS) / Dysthymic Disorder / Major Depressive Disorder (MDD)1
4WithdrawnTreatmentMethamphetamine Dependence1
Not AvailableActive Not RecruitingTreatmentSchizophrenia Relapse1
Not AvailableCompletedNot AvailableBipolar Disorder (BD)1
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Metabolic Syndromes / Psychotic Disorder NOS1
Not AvailableCompletedNot AvailableBipolar Disorder (BD) / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Type 2 Diabetes Mellitus1
Not AvailableCompletedNot AvailableNormal Volunteers1
Not AvailableCompletedNot AvailableSchizoaffective Disorders / Schizophenia Disorder1
Not AvailableCompletedBasic ScienceAntipsychotics / Brain Metabolism / Cognition / Dopamine Receptor Occupancy1
Not AvailableCompletedDiagnosticSchizophrenic Disorders1
Not AvailableCompletedPreventionBipolar Disorder (BD) / Depression / Psychotic Disorder NOS / Schizophrenic Disorders1
Not AvailableCompletedTreatmentAttention Deficit Hyperactivity Disorder (ADHD) / Bipolar Disorder (BD)1
Not AvailableCompletedTreatmentAutism, Early Infantile1
Not AvailableCompletedTreatmentBipolar Disorder (BD)1
Not AvailableCompletedTreatmentMajor Depressive Disorder (MDD)1
Not AvailableCompletedTreatmentMetabolic Syndromes1
Not AvailableCompletedTreatmentObsessive Compulsive Disorder (OCD) / Schizophrenia OCD1
Not AvailableCompletedTreatmentTrichotillomania1
Not AvailableCompletedTreatmentIdiopathic hyperprolactinemic disorder1
Not AvailableEnrolling by InvitationNot AvailableBipolar Disorder (BD)1
Not AvailableNot Yet RecruitingTreatmentObsessive-Compulsive Disorder (OCD)1
Not AvailableNot Yet RecruitingTreatmentSchizophrenic Disorders1
Not AvailableRecruitingNot AvailableAcute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Decompensated Heart Failure (ADHF) / Acute Pyelonephritis / Adenovirus / Adjunct to general anesthesia therapy / Adrenal Insufficiency / Airway Swelling / Anaesthesia therapy / Anxiolysis / Arterial Hypotension / Autism, Early Infantile / Autistic Disorder / Bartonellosis / Benzodiazepine Withdrawal / Benzodiazepines / Bipolar Disorder (BD) / Bloodstream Infections / Bone and Joint Infections / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest / Central Nervous System Infections / Cholera / Chronic Bacterial Prostatitis / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infections / Convulsions / Cyanide Poisoning / Cytomegalovirus Retinitis / Drug hypersensitivity reaction / Early-onset Schizophrenia Spectrum Disorders / Edema / Epilepsies / Feeling Anxious / Flu caused by Influenza / Gastroparesis / GYNAECOLOGICAL INFECTION / Headaches / Herpes Simplex Virus / High Blood Pressure (Hypertension) / Hospital-acquired bacterial pneumonia / Hypercholesterolaemia / Hyperlipidemias / Infantile Hemangiomas / Infection NOS / Inflammatory Conditions / Inflammatory Reaction / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Intra-Abdominal Infections / Life-threatening Fungal Infections / Lower Respiratory Tract Infection (LRTI) / Meningitis, Bacterial / Migraines / Muscle Spasms / Nausea / Opioid Addiction / Pain / Plague / Pneumonia / Prophylaxis / Psittacosis / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenic Disorders / Sedation therapy / Seizures / Sepsis / Skeletal Muscle Spasms / Skin and Subcutaneous Tissue Bacterial Infections / Skin Structures and Soft Tissue Infections / Stable Angina (SA) / Thromboprophylaxis / Thrombosis / Trachoma / Treatment-resistant Schizophrenia / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Urinary Tract Infections (UTIs) / Vomiting / Withdrawal1
Not AvailableRecruitingNot AvailableAdhd / Anorexia Nervosa (AN) / Depression1
Not AvailableRecruitingNot AvailableBipolar Disorder (BD)1
Not AvailableRecruitingNot AvailableBipolar Disorder (BD) / First-Episode Psychosis1
Not AvailableRecruitingNot AvailableSchizophrenic Disorders1
Not AvailableRecruitingOtherBioequivalence1
Not AvailableRecruitingTreatmentSchizophrenic Disorders1
Not AvailableTerminatedNot AvailableSchizophrenic Disorders1
Not AvailableTerminatedTreatmentBipolar Disorder (BD) / Metabolic Syndromes1
Not AvailableTerminatedTreatmentGilles de la Tourette's Syndrome1
Not AvailableTerminatedTreatmentProdromal Psychosis / Prodromal Schizophrenia1
Not AvailableTerminatedTreatmentSchizoaffective Disorders / Schizophrenic Disorders2
Not AvailableUnknown StatusPreventionPsychotic Disorder NOS1
Not AvailableUnknown StatusTreatmentMajor Depressive Disorder (MDD)2
Not AvailableUnknown StatusTreatmentSchizophrenic Disorders2
Not AvailableUnknown StatusTreatmentSchizophrenic Disorders / Sensory Gating1
Not AvailableWithdrawnTreatmentPsychotic Disorder NOS1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntramuscular9.75 mg/1.3mL
SolutionOral1 mg/mL
TabletOral10.0 mg
TabletOral15.0 mg
TabletOral2 mg/1
TabletOral2.0 mg
TabletOral20.0 mg
TabletOral30 mg/1
TabletOral30.0 mg
TabletOral5 mg/1
TabletOral5.0 mg
Injection, powder, for suspension, extended releaseIntramuscular300 mg
Injection, powder, for suspension, extended releaseIntramuscular400 mg
Injection, powder, for suspension, extended release; kitIntramuscular300 mg
Injection, powder, for suspension, extended release; kitIntramuscular400 mg
Kit
TabletOral10 mg/1
TabletOral15 mg/1
TabletOral20 mg/1
Tablet, orally disintegratingOral10 mg/1
Tablet, orally disintegratingOral15 mg/1
TabletOral10 mg
TabletOral15 mg
TabletOral30 mg
TabletOral5 mg
TabletOral20 mg
Tablet, orally disintegratingOral10 mg
Tablet, orally disintegratingOral15 mg
Tablet, orally disintegratingOral30 mg
Injection, suspension, extended releaseIntramuscular1064 mg/3.9mL
Injection, suspension, extended releaseIntramuscular441 mg/1.6mL
Injection, suspension, extended releaseIntramuscular662 mg/2.4mL
Injection, suspension, extended releaseIntramuscular882 mg/3.2mL
Prices
Unit descriptionCostUnit
Abilify Discmelt 30 10 mg Dispersible Tablet Box636.3USD box
Abilify 30 mg tablet32.12USD tablet
Abilify 15 mg tablet26.07USD tablet
Abilify 10 mg tablet23.53USD tablet
Abilify 5 mg tablet23.53USD tablet
Abilify 2 mg tablet22.25USD tablet
Abilify 20 mg tablet21.99USD tablet
Abilify discmelt 10 mg tablet20.39USD tablet
Abilify discmelt 15 mg tablet20.39USD tablet
Abilify 9.7 mg/1.3 ml vial16.04USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5006528No1994-10-202014-10-20Us
US7053092No2002-01-282022-01-28Us
US8642600Yes2002-07-282022-07-28Us
US8759350No2007-03-022027-03-02Us
US9125939No2006-07-282026-07-28Us
US9089567No2002-01-282022-01-28Us
US8017615Yes2004-12-162024-12-16Us
US8580796Yes2003-03-252023-03-25Us
US8642760Yes2003-03-252023-03-25Us
US6977257Yes2002-10-242022-10-24Us
US8518421Yes2001-07-242021-07-24Us
US7115587Yes2005-01-212025-01-21Us
US7550445Yes2005-01-212025-01-21Us
US8030313No2004-10-192024-10-19Us
US8338427No2005-03-152025-03-15Us
US8338428No2003-08-062023-08-06Us
US8759351No2003-08-062023-08-06Us
US7807680No2004-10-192024-10-19Us
US8993761No2002-09-252022-09-25Us
US8722679No2004-10-192024-10-19Us
US8399469No2005-06-292025-06-29Us
US9193685No2013-10-242033-10-24Us
US8796276No2010-06-242030-06-24Us
US9034867No2012-11-072032-11-07Us
US8431576No2010-10-262030-10-26Us
US9387182No2003-12-252023-12-25Us
US9359302No2002-09-252022-09-25Us
US9358207No2000-04-122020-04-12Us
US9526726No2015-03-192035-03-19Us
US9452131No2015-03-192035-03-19Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP4.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00777 mg/mLALOGPS
logP5.21ALOGPS
logP4.9ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)13.51ChemAxon
pKa (Strongest Basic)7.46ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area44.81 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity124.34 m3·mol-1ChemAxon
Polarizability49.23 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9934
Blood Brain Barrier+0.992
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.7431
P-glycoprotein inhibitor IInhibitor0.9585
P-glycoprotein inhibitor IIInhibitor0.9321
Renal organic cation transporterInhibitor0.5175
CYP450 2C9 substrateNon-substrate0.8663
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7408
CYP450 1A2 substrateInhibitor0.6581
CYP450 2C9 inhibitorInhibitor0.6682
CYP450 2D6 inhibitorInhibitor0.6633
CYP450 2C19 inhibitorInhibitor0.8934
CYP450 3A4 inhibitorInhibitor0.5256
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9104
Ames testNon AMES toxic0.6124
CarcinogenicityNon-carcinogens0.8765
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.8894 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.62
hERG inhibition (predictor II)Inhibitor0.8814
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0f72-0340900000-34d93478ad0d9f5cf2b0
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-3970100000-6b98b53e8175df39986e

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
Phenylpiperazines
Alternative Parents
N-arylpiperazines / Hydroquinolones / Hydroquinolines / Dichlorobenzenes / Dialkylarylamines / Aniline and substituted anilines / N-alkylpiperazines / Alkyl aryl ethers / Aryl chlorides / Secondary carboxylic acid amides
show 9 more
Substituents
Phenylpiperazine / N-arylpiperazine / Tetrahydroquinolone / Quinolone / Tetrahydroquinoline / 1,2-dichlorobenzene / Tertiary aliphatic/aromatic amine / Aniline or substituted anilines / Dialkylarylamine / Alkyl aryl ether
show 28 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
N-arylpiperazine, dichlorobenzene, N-alkylpiperazine, quinolone (CHEBI:31236)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Meltzer HY, Li Z, Kaneda Y, Ichikawa J: Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1159-72. [PubMed:14642974]
  2. Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry Kannan T, Molski TF, Yocca FD, Sharp T, Kikuchi T, Burris KD: Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology (Berl). 2007 Feb;190(3):373-82. Epub 2006 Nov 25. [PubMed:17242925]
  3. Bortolozzi A, Diaz-Mataix L, Toth M, Celada P, Artigas F: In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology (Berl). 2007 Apr;191(3):745-58. Epub 2007 Jan 30. [PubMed:17265076]
Details
2. D(2) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
Partial agonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Hirose T, Kikuchi T: Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist. J Med Invest. 2005 Nov;52 Suppl:284-90. [PubMed:16366516]
  2. Inoue A, Miki S, Seto M, Kikuchi T, Morita S, Ueda H, Misu Y, Nakata Y: Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol. 1997 Feb 19;321(1):105-11. [PubMed:9083792]
  3. Wood MD, Scott C, Clarke K, Westaway J, Davies CH, Reavill C, Hill M, Rourke C, Newson M, Jones DN, Forbes IT, Gribble A: Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. Eur J Pharmacol. 2006 Sep 28;546(1-3):88-94. Epub 2006 Jul 21. [PubMed:16925992]
  4. Kim E, Yu KS, Cho JY, Shin YW, Yoo SY, Kim YY, Jang IJ, Shin SG, Kwon JS: Effects of DRD2 and CYP2D6 genotypes on delta EEG power response to aripiprazole in healthy male volunteers: a preliminary study. Hum Psychopharmacol. 2006 Dec;21(8):519-28. [PubMed:16981227]
  5. Wood M, Reavill C: Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert Opin Investig Drugs. 2007 Jun;16(6):771-5. [PubMed:17501690]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
Partial agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA: The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002 Apr 26;441(3):137-40. [PubMed:12063084]
  2. Marona-Lewicka D, Nichols DE: Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats. Psychopharmacology (Berl). 2004 Apr;172(4):415-21. Epub 2003 Nov 28. [PubMed:14647959]
  3. Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA: In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol. 2004 Jan 1;483(1):45-53. [PubMed:14709325]
  4. Swainston Harrison T, Perry CM: Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715-36. [PubMed:15257633]
  5. Cosi C, Waget A, Rollet K, Tesori V, Newman-Tancredi A: Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation. Brain Res. 2005 May 10;1043(1-2):32-41. [PubMed:15862515]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1B
Uniprot ID
P28222
Uniprot Name
5-hydroxytryptamine receptor 1B
Molecular Weight
43567.535 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive subst...
Gene Name
HTR1D
Uniprot ID
P28221
Uniprot Name
5-hydroxytryptamine receptor 1D
Molecular Weight
41906.38 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that trig...
Gene Name
HTR1E
Uniprot ID
P28566
Uniprot Name
5-hydroxytryptamine receptor 1E
Molecular Weight
41681.57 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Voltage-gated potassium channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3A
Uniprot ID
P46098
Uniprot Name
5-hydroxytryptamine receptor 3A
Molecular Weight
55279.835 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR6
Uniprot ID
P50406
Uniprot Name
5-hydroxytryptamine receptor 6
Molecular Weight
46953.625 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR7
Uniprot ID
P34969
Uniprot Name
5-hydroxytryptamine receptor 7
Molecular Weight
53554.43 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Details
11. D(1A) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
Partial agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD1
Uniprot ID
P21728
Uniprot Name
D(1A) dopamine receptor
Molecular Weight
49292.765 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Details
12. D(1B) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
Partial agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name
DRD5
Uniprot ID
P21918
Uniprot Name
D(1B) dopamine receptor
Molecular Weight
52950.5 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Details
13. D(3) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
Partial agonist
General Function
G-protein coupled amine receptor activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name
DRD3
Uniprot ID
P35462
Uniprot Name
D(3) dopamine receptor
Molecular Weight
44224.335 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Details
14. D(4) dopamine receptor
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
Partial agonist
General Function
Sh3 domain binding
Specific Function
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins ...
Gene Name
DRD4
Uniprot ID
P21917
Uniprot Name
D(4) dopamine receptor
Molecular Weight
48359.86 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Details
15. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name
ADRA2A
Uniprot ID
P08913
Uniprot Name
Alpha-2A adrenergic receptor
Molecular Weight
48956.275 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
Other/unknown
General Function
Protein homodimerization activity
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name
ADRA2C
Uniprot ID
P18825
Uniprot Name
Alpha-2C adrenergic receptor
Molecular Weight
49521.585 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM4
Uniprot ID
P08173
Uniprot Name
Muscarinic acetylcholine receptor M4
Molecular Weight
53048.65 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM5
Uniprot ID
P08912
Uniprot Name
Muscarinic acetylcholine receptor M5
Molecular Weight
60073.205 Da
References
  1. Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11. [PubMed:17848919]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18